Krajina: Kanada
Jazyk: angličtina
Zdroj: Health Canada
FINGOLIMOD (FINGOLIMOD HYDROCHLORIDE)
ASCEND LABORATORIES LTD
L04AA27
FINGOLIMOD
0.5MG
CAPSULE
FINGOLIMOD (FINGOLIMOD HYDROCHLORIDE) 0.5MG
ORAL
100
Prescription
Immunomodulatory Agents
Active ingredient group (AIG) number: 0152886001; AHFS:
APPROVED
2020-06-23
_Page 1 of 64 _ PRODUCT MONOGRAPH PR ASN-FINGOLIMOD Fingolimod capsules 0.5 mg fingolimod capsules (as fingolimod hydrochloride) Sphingosine 1-phosphate receptor modulator Ascend Laboratories Ltd. 35 Nixon Road, Unit 10 Caledon, Ontario L7E 1K1 Date of Approval: June 18, 2020 Submission Control No: 231582 _Page 2 of 64 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................5 ADVERSE REACTIONS ..................................................................................................25 DRUG INTERACTIONS ..................................................................................................33 DOSAGE AND ADMINISTRATION ..............................................................................36 OVERDOSAGE ................................................................................................................39 ACTION AND CLINICAL PHARMACOLOGY ............................................................40 STORAGE AND STABILITY ..........................................................................................45 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................45 PART II: SCIENTIFIC INFORMATION ...............................................................................46 PHARMACEUTICAL INFORMATION ..........................................................................46 CLINICAL TRIALS ..........................................................................................................47 DETAILED PHARMACOLOGY ................................. Prečítajte si celý dokument